Table of Content

1 INTRODUCTION (Page No. - 39)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 CANCER/TUMOR PROFILING MARKET
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED
          TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS:
    1.4 STAKEHOLDERS
    1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 43)
    2.1 RESEARCH APPROACH
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                    2.1.2.3 Breakdown of primaries
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZING & VALIDATION APPROACH
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS
          FIGURE 7 TOP-DOWN APPROACH
          FIGURE 8 CAGR PROJECTIONS
          FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
    2.3 DATA TRIANGULATION APPROACH
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 STUDY ASSUMPTIONS
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
          TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET

3 EXECUTIVE SUMMARY (Page No. - 56)
    FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS (Page No. - 61)
    4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
          FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021)
          FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
    4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX  (2022–2027)
          FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027)
          FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of cancer
                                FIGURE 22 GLOBAL CANCER INCIDENCE, 2008–2030
                    5.2.1.2 Increasing use of biomarkers in cancer profiling
                    5.2.1.3 Growing investments in cancer research
                    5.2.1.4 Technological advancements in cancer profiling techniques
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investments for biomarker discovery & development
                                TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT
                    5.2.2.2 Technical issues related to sample collection & storage
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing preference for personalized medicine
                                FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021
                    5.2.3.2 Rising need for point-of-care diagnostics
                                TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE)
           5.2.4 CHALLENGES
                    5.2.4.1 Low biomarker discovery-to-approval ratio
                                FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS
                    5.2.4.2 Poor regulatory and reimbursement scenario
                                TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 INDUSTRY TRENDS
           5.3.1 INTEGRATION OF OMICS DATA
                    TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES
           5.3.2 ADVANCES IN LIQUID BIOPSY
           5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE
                    TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021)
           5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES

6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (Page No. - 80)
    6.1 INTRODUCTION
          TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
          TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027(USD MILLION)
    6.2 IMMUNOASSAYS
           6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET
                    TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2027 (USD MILLION)
    6.3 NEXT-GENERATION SEQUENCING
           6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET
                    TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2027 (USD MILLION)
    6.4 POLYMERASE CHAIN REACTION
           6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION  TO DRIVE MARKET
                    TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2027 (USD MILLION)
    6.5 IN SITU HYBRIDIZATION
           6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET
                    TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2027 (USD MILLION)
    6.6 MICROARRAYS
           6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET
                    TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2027 (USD MILLION)
    6.7 MASS SPECTROMETRY
           6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET
                    TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2027 (USD MILLION)
    6.8 OTHER TECHNOLOGIES
          TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022–2027 (USD MILLION)

7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (Page No. - 97)
    7.1 INTRODUCTION
          TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
          TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
    7.2 BREAST CANCER
           7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET
                    TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2027 (USD MILLION)
    7.3 LUNG CANCER
           7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET
                    FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012−2030
                    TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2027 (USD MILLION)
    7.4 COLORECTAL CANCER
           7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET
                    FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018)
                    TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2027 (USD MILLION)
    7.5 PROSTATE CANCER
           7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET
                    FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020)
                    TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2027 (USD MILLION)
    7.6 MELANOMA
           7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS  TO DRIVE MARKET
                    TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022–2027 (USD MILLION)
    7.7 OTHER CANCERS
          FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020)
          TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022–2027 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE (Page No. - 113)
    8.1 INTRODUCTION
          TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
          TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
    8.2 GENETIC BIOMARKERS
           8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES
                    TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION)
    8.3 PROTEIN BIOMARKERS
           8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS
                    TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION)
                    TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION)
    8.4 OTHER BIOMARKERS
          TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION (Page No. - 121)
    9.1 INTRODUCTION
          TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
          TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
    9.2 RESEARCH APPLICATIONS
          TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
          TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
          TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION)
           9.2.1 BIOMARKER DISCOVERY
                    9.2.1.1 Development of personalized medicine and drug development to support market
                                TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022–2027 (USD MILLION)
           9.2.2 PERSONALIZED MEDICINE
                    9.2.2.1 Rising funding activities in precision medicine to support market
                                TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2027 (USD MILLION)
    9.3 CLINICAL APPLICATIONS
          TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
          TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
          TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION)
           9.3.1 DIAGNOSTICS
                    9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market
                                TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION)
           9.3.2 PROGNOSTICS
                    9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling
                                TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION)
           9.3.3 MONITORING & TREATMENT
                    9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market
                                TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022–2027 (USD MILLION)
           9.3.4 SCREENING
                    9.3.4.1 Screening tests to help high-risk patients ascertain outcomes
                                TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018–2021 (USD MILLION)
                                TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022–2027 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY REGION (Page No. - 138)
     10.1 INTRODUCTION
             FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021)
             TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018–2021 (USD MILLION)
             TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022–2027 (USD MILLION)
     10.2 NORTH AMERICA
             TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020)
             FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
             FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
             TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
             TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
             TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
             TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
             TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
             TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
             TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
             TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
             TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
             TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 High R&D investments for cancer biomarker research to drive market
                                      TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market
                                      TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
     10.3 EUROPE
            FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
            TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
            TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
            TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
            TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
            TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
            TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
            TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
            TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
            TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
            TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
            TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
            TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Favorable government health policies to drive market
                                      TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market
                                      TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Growing government investments in genomics & proteomics research to drive market
                                      TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market
                                      TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Rising incidence of cancer to drive demand for biomarkers
                                      TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.3.6 REST OF EUROPE (ROE)
                        TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                        TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                        TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                        TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                        TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                        TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                        TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                        TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
     10.4 ASIA PACIFIC
            FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
            FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
            TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
            TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
            TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
            TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
            TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
            TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
            TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
            TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
            TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
            TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022–2027 (USD MILLION)
            TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
            TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Increasing initiatives to boost genomic research to support market
                                      TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products
                                      TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market
                                      TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                                      TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                                      TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                                      TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                                      TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                                      TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                                      TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                        TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                        TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                        TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                        TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                        TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                        TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                        TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 GROWING RESEARCH ACTIVITIES IN PRECISION ONCOLOGY TO SUPPORT MARKET
                        TABLE 241 LATIN AMERICA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
                        TABLE 242 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                        TABLE 243 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                        TABLE 244 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                        TABLE 245 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                        TABLE 246 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                        TABLE 247 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                        TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 249 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                        TABLE 250 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 251 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 GROWING ESTABLISHMENT OF PHARMA RESEARCH COMPANIES TO DRIVE DEMAND FOR CANCER DIAGNOSTICS
                        TABLE 252 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION)
                        TABLE 253 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION)
                        TABLE 254 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION)
                        TABLE 255 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION)
                        TABLE 256 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION)
                        TABLE 257 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION)
                        TABLE 258 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 259 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
                        TABLE 260 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION)
                        TABLE 261 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 227)
     11.1 OVERVIEW
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
     11.4 MARKET SHARE ANALYSIS
             FIGURE 36 NEXT-GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER (2021)
             FIGURE 37 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER (2021)
             FIGURE 38 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER (2021)
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION  QUADRANT (2021)
     11.6 COMPETITIVE SCENARIO
             11.6.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 262 PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–OCTOBER 2022)
             11.6.2 DEALS
                        TABLE 263 DEALS (JANUARY 2019–OCTOBER 2022)
             11.6.3 OTHERS
                        TABLE 264 OTHERS (JANUARY 2019–OCTOBER 2022)

12 COMPANY PROFILES (Page No. - 234)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 ILLUMINA, INC.
                        TABLE 265 ILLUMINA, INC: BUSINESS OVERVIEW
                        FIGURE 40 ILLUMINA, INC: COMPANY SNAPSHOT (2021)
             12.1.2 QIAGEN N.V.
                        TABLE 266 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.3 NEOGENOMICS, INC.
                        TABLE 267 NEOGENOMICS, INC: BUSINESS OVERVIEW
                        FIGURE 42 NEOGENOMICS, INC: COMPANY SNAPSHOT (2021)
             12.1.4 SYSMEX CORPORATION
                        TABLE 268 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.5 HTG MOLECULAR DIAGNOSTICS, INC.
                        TABLE 269 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021)
             12.1.6 PREDICTIVE ONCOLOGY, INC. (HELOMICS CORPORATION)
                        TABLE 270 PREDICTIVE ONCOLOGY, INC.: BUSINESS OVERVIEW
                        FIGURE 45 PREDICTIVE ONCOLOGY, INC: COMPANY SNAPSHOT (2021)
             12.1.7 CARIS LIFE SCIENCES
                        TABLE 271 CLARIS LIFE SCIENCES: BUSINESS OVERVIEW
             12.1.8 NANOSTRING TECHNOLOGIES, INC.
                        TABLE 272 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 46 NANOSTRING TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021)
             12.1.9 GUARDANT HEALTH, INC.
                        TABLE 273 GUARDANT HEALTH, INC: BUSINESS OVERVIEW
                        FIGURE 47 GUARDANT HEALTH, INC: COMPANY SNAPSHOT (2021)
             12.1.10 FOUNDATION MEDICINE, INC.
                        TABLE 274 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
             12.1.11 F. HOFFMANN-LA ROCHE LTD
                        TABLE 275 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
                        FIGURE 48 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
             12.1.12 THERMO FISHER SCIENTIFIC INC.
                        TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 49 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2021)
             12.1.13 GENSCRIPT BIOTECH CORPORATION
                        TABLE 277 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
                        FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.14 TEMPUS LABS
                        TABLE 278 TEMPUS LABS: BUSINESS OVERVIEW
             12.1.15 HOLOGIC, INC.
                        TABLE 279 HOLOGIC, INC: BUSINESS OVERVIEW
                        FIGURE 51 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
             12.1.16 EXACT SCIENCES
                        TABLE 280 EXACT SCIENCES: BUSINESS OVERVIEW
                        FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2021)
             12.1.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 281 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 53 LABORATORY CORPORATION OF AMERICA HOLDINGS:  COMPANY SNAPSHOT (2021)
             12.1.18 PERSONALIS, INC.
                        TABLE 282 PERSONALIS, INC: BUSINESS OVERVIEW
                        FIGURE 54 PERSONALIS, INC.: COMPANY SNAPSHOT (2021)
     12.2 OTHER PLAYERS
             12.2.1 BOREAL GENOMICS INC.
                        TABLE 283 BOREAL GENOMICS, INC: BUSINESS OVERVIEW
             12.2.2 STRAND LIFE SCIENCES
                        TABLE 284 STRAND LIFE SCIENCES: BUSINESS OVERVIEW
             12.2.3 LUCENCE HEALTH, INC.
                        TABLE 285 LUCENCE HEALTH, INC.: BUSINESS OVERVIEW
             12.2.4 ACT GENOMICS CO., LTD.
                        TABLE 286 ACT GENOMICS CO., LTD.: BUSINESS OVERVIEW
             12.2.5 IMB DX, INC.
                        TABLE 287 IMB DX, INC.: BUSINESS OVERVIEW
             12.2.6 PERTHERA
                        TABLE 288 PERTHERA: BUSINESS OVERVIEW
             12.2.7 AGENDIA
                        TABLE 289 AGENDIA: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 297)
     13.1 INSIGHTS FROM INDUSTRY EXPERTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 CUSTOMIZATION OPTIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS



List of Tables

10.5 LATIN AMERICA 216
10.5.1 GROWING RESEARCH ACTIVITIES IN PRECISION ONCOLOGY TO SUPPORT MARKET 216
TABLE 241 LATIN AMERICA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 217
TABLE 242 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 217
TABLE 243 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 218
TABLE 244 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 218
TABLE 245 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 219
TABLE 246 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 219
TABLE 247 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 219
TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 220
TABLE 249 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 220
TABLE 250 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 220
TABLE 251 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 221
10.6 MIDDLE EAST & AFRICA 221
10.6.1 GROWING ESTABLISHMENT OF PHARMA RESEARCH COMPANIES TO DRIVE DEMAND FOR CANCER DIAGNOSTICS 221
TABLE 252 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 222
TABLE 253 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 223
TABLE 254 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 223
TABLE 255 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 224
TABLE 256 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 224
TABLE 257 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 224
TABLE 258 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 225
TABLE 259 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 225
TABLE 260 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 225
TABLE 261 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 226
11 COMPETITIVE LANDSCAPE 227
11.1 OVERVIEW 227
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 227
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 227
11.4 MARKET SHARE ANALYSIS 228
FIGURE 36 NEXT-GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER (2021) 228
FIGURE 37 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER (2021) 229
FIGURE 38 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER (2021) 229
11.5 COMPANY EVALUATION QUADRANT 230
11.5.1 STARS 230
11.5.2 EMERGING LEADERS 230
11.5.3 PERVASIVE PLAYERS 230
11.5.4 PARTICIPANTS 231
FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION QUADRANT (2021) 231
11.6 COMPETITIVE SCENARIO 231
11.6.1 PRODUCT LAUNCHES & APPROVALS 232
TABLE 262 PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–OCTOBER 2022) 232
11.6.2 DEALS 232
TABLE 263 DEALS (JANUARY 2019–OCTOBER 2022) 232
11.6.3 OTHERS 233
TABLE 264 OTHERS (JANUARY 2019–OCTOBER 2022) 233
12 COMPANY PROFILES 234
12.1 KEY PLAYERS 234
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ILLUMINA, INC. 234
TABLE 265 ILLUMINA, INC: BUSINESS OVERVIEW 234
FIGURE 40 ILLUMINA, INC: COMPANY SNAPSHOT (2021) 235
12.1.2 QIAGEN N.V. 240
TABLE 266 QIAGEN N.V.: BUSINESS OVERVIEW 240
FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 241
12.1.3 NEOGENOMICS, INC. 245
TABLE 267 NEOGENOMICS, INC: BUSINESS OVERVIEW 245
FIGURE 42 NEOGENOMICS, INC: COMPANY SNAPSHOT (2021) 246
12.1.4 SYSMEX CORPORATION 249
TABLE 268 SYSMEX CORPORATION: BUSINESS OVERVIEW 249
FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 250
12.1.5 HTG MOLECULAR DIAGNOSTICS, INC. 253
TABLE 269 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW 253
FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021) 254
12.1.6 PREDICTIVE ONCOLOGY, INC. (HELOMICS CORPORATION) 256
TABLE 270 PREDICTIVE ONCOLOGY, INC.: BUSINESS OVERVIEW 256
FIGURE 45 PREDICTIVE ONCOLOGY, INC: COMPANY SNAPSHOT (2021) 256
12.1.7 CARIS LIFE SCIENCES 258
TABLE 271 CLARIS LIFE SCIENCES: BUSINESS OVERVIEW 258
12.1.8 NANOSTRING TECHNOLOGIES, INC. 259
TABLE 272 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW 259
FIGURE 46 NANOSTRING TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021) 260
12.1.9 GUARDANT HEALTH, INC. 263
TABLE 273 GUARDANT HEALTH, INC: BUSINESS OVERVIEW 263
FIGURE 47 GUARDANT HEALTH, INC: COMPANY SNAPSHOT (2021) 264
12.1.10 FOUNDATION MEDICINE, INC. 266
TABLE 274 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW 266
12.1.11 F. HOFFMANN-LA ROCHE LTD 267
TABLE 275 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 267
FIGURE 48 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021) 268
12.1.12 THERMO FISHER SCIENTIFIC INC. 270
TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 270
FIGURE 49 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2021) 271
12.1.13 GENSCRIPT BIOTECH CORPORATION 273
TABLE 277 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW 273
FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) 274
12.1.14 TEMPUS LABS 275
TABLE 278 TEMPUS LABS: BUSINESS OVERVIEW 275
12.1.15 HOLOGIC, INC. 277
TABLE 279 HOLOGIC, INC: BUSINESS OVERVIEW 277
FIGURE 51 HOLOGIC, INC: COMPANY SNAPSHOT (2021) 278
12.1.16 EXACT SCIENCES 279
TABLE 280 EXACT SCIENCES: BUSINESS OVERVIEW 279
FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2021) 280
12.1.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 282
TABLE 281 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 282
FIGURE 53 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021) 283
12.1.18 PERSONALIS, INC. 285
TABLE 282 PERSONALIS, INC: BUSINESS OVERVIEW 285
FIGURE 54 PERSONALIS, INC.: COMPANY SNAPSHOT (2021) 285
12.2 OTHER PLAYERS 287
12.2.1 BOREAL GENOMICS INC. 287
TABLE 283 BOREAL GENOMICS, INC: BUSINESS OVERVIEW 287
12.2.2 STRAND LIFE SCIENCES 288
TABLE 284 STRAND LIFE SCIENCES: BUSINESS OVERVIEW 288
12.2.3 LUCENCE HEALTH, INC. 289
TABLE 285 LUCENCE HEALTH, INC.: BUSINESS OVERVIEW 289
12.2.4 ACT GENOMICS CO., LTD. 291
TABLE 286 ACT GENOMICS CO., LTD.: BUSINESS OVERVIEW 291
12.2.5 IMB DX, INC. 293
TABLE 287 IMB DX, INC.: BUSINESS OVERVIEW 293
12.2.6 PERTHERA 294
TABLE 288 PERTHERA: BUSINESS OVERVIEW 294
12.2.7 AGENDIA 295
TABLE 289 AGENDIA: BUSINESS OVERVIEW 295
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 297
13.1 INSIGHTS FROM INDUSTRY EXPERTS 297
13.2 DISCUSSION GUIDE 298
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303
13.4 CUSTOMIZATION OPTIONS 305
13.5 RELATED REPORTS 305
13.6 AUTHOR DETAILS 306